Natco Pharma Financial Statements

Natco Pharma (NATCOPHARM) reported revenue of ₹47.84B in FY2025 with net income of ₹18.83B. Total assets stood at ₹86.31B and free cash flow was ₹8.72B.

Natco Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		21.56B	20.44B	28.12B	41.27B	47.84B
Cost of Rev. Cost of Revenue		-5.11B	-5.61B	-6.27B	-7.17B	-6.90B
Gross Profit		16.44B	14.83B	21.84B	34.10B	40.94B
SGA Sales, General & Admin		-9.35B	-11.20B	-11.44B	-15.31B	-15.44B
Op. Income Operating Income		5.93B	2.20B	8.76B	16.93B	23.15B
PBT Profit Before Tax		5.76B	2.02B	8.62B	16.74B	22.91B
Net Income		4.40B	1.70B	7.15B	13.88B	18.83B
Dil. Shares Diluted Shares		182.49M	182.41M	182.55M	179.50M	179.11M
Diluted EPS		24.12	9.32	39.18	77.34	105.26

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Natco Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Natco Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		23.37B	24.87B	30.00B	40.24B	52.70B
Non-curr. assets Total non-current assets		24.55B	26.22B	26.57B	28.83B	33.61B
Total assets		47.92B	51.09B	56.57B	69.06B	86.31B
Curr. liabilities Total current liabilities		5.26B	7.10B	6.83B	9.73B	9.44B
Non-curr. liab. Total non-current liabilities		1.43B	1.35B	1.01B	804.00M	750.00M
Total liabilities		6.69B	8.46B	7.84B	10.53B	10.19B
Total equity		41.23B	42.64B	48.74B	58.53B	76.12B
Total liab. & eq. Total liabilities & equity		47.92B	51.09B	56.57B	69.06B	86.31B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Natco Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Natco Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2020 – FY 2024

Item	Chart	2020	2021	2022	2023	2024
Net Income		5.69B	5.80B	2.02B	8.62B	16.74B
Operating CF Cash flow Operating Activities		4.17B	2.99B	465.00M	8.49B	12.12B
Capex Investments in PPE		-3.56B	-2.55B	-2.33B	-1.46B	-3.39B
Investing CF Cash flow Investing Activities		-1.67B	-1.03B	-53.00M	-4.77B	-10.33B
Dividend Paid		-1.54B	-1.14B	-822.00M	-1.00B	-1.71B
Financing CF Cash flow Financing Activities		-2.51B	-1.86B	348.00M	-3.63B	-2.47B
Cash (start) Cash at beginning of period		283.00M	198.00M	258.00M	1.11B	1.32B
Cash (end) Cash at end of period		198.00M	258.00M	1.11B	1.32B	704.00M
FCF Free Cash Flow		615.00M	442.00M	-1.86B	7.03B	8.72B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Natco Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025